Palette Life Sciences Signs a Worldwide Commercialization and Development Agreement with Nestle Skin Health
Shots:
- Palette to receive global development rights for Nestle’s Deflux- Solesta and Barrigel and will focus on its commercialization. Nestle will continue to develop the license products for Palette
- The licensed products are developed by using Nestle’s NASHA technology- used for injecting and creating firm gel texture. Additionally- Pharmanest AB will be renamed as Palette Life Sciences AB in Sweden and the US
- Deflux IV & Solesta are novel FDA approved treatments for vesicoureteral reflux (VUR) & fecal incontinence respectively. Barrigel IV is EU approved treatment for protection of the rectal wall when treating prostate cancer with radiation
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
